Evaluation of organ motion-based robust optimisation for VMAT planning for breast and internal mammary chain radiotherapy

Aims: In patients undergoing locoregional radiotherapy (RT) for breast cancer including the internal mammary chain (IMC), VMAT has been shown to be superior to tangential-field radiotherapy in terms of target coverage and minimising dose to heart and lungs. In this study we describe and validate org...

Full description

Bibliographic Details
Main Authors: Alex Dunlop, Ruth Colgan, Anna Kirby, Alison Ranger, Irena Blasiak-Wal
Format: Article
Language:English
Published: Elsevier 2019-05-01
Series:Clinical and Translational Radiation Oncology
Online Access:http://www.sciencedirect.com/science/article/pii/S2405630819300187
id doaj-1b870275782a4eb093fc3fb17f589f08
record_format Article
spelling doaj-1b870275782a4eb093fc3fb17f589f082021-06-02T15:24:45ZengElsevierClinical and Translational Radiation Oncology2405-63082019-05-01166066Evaluation of organ motion-based robust optimisation for VMAT planning for breast and internal mammary chain radiotherapyAlex Dunlop0Ruth Colgan1Anna Kirby2Alison Ranger3Irena Blasiak-Wal4The Joint Department of Physics, The Institute of Cancer Research and The Royal Marsden Hospital, Downs Rd, Sutton SM2 5PT, UK; Corresponding author.The Joint Department of Physics, The Institute of Cancer Research and The Royal Marsden Hospital, Downs Rd, Sutton SM2 5PT, UKThe Royal Marsden NHS Foundation Trust, London, UKThe Royal Marsden NHS Foundation Trust, London, UK; The Institute of Cancer Research, London, UKThe Joint Department of Physics, The Institute of Cancer Research and The Royal Marsden Hospital, Downs Rd, Sutton SM2 5PT, UKAims: In patients undergoing locoregional radiotherapy (RT) for breast cancer including the internal mammary chain (IMC), VMAT has been shown to be superior to tangential-field radiotherapy in terms of target coverage and minimising dose to heart and lungs. In this study we describe and validate organ motion-based robust optimisation for generating breast and locoregional lymph node VMAT plans that are robust to inter-fractional changes. Materials and methods: In this retrospective study of five patients with left-sided breast cancer requiring locoregional breast radiotherapy including the IMC, non-robust plans were generated in the nominal scenario (planning-CT) and corresponding robust plans were created by optimising over a range of simulated CTs representing worst-case scenario shape changes to the breast. Both plans were re-calculated on CBCT images (n = 67) acquired prior to RT to generate estimates of delivered fractional dose. Plan robustness to inter-fractional changes was assessed in terms of the estimated target coverage and OAR dose. Results: Organ motion-based robust optimisation was able to generate clinically acceptable treatment plans in the nominal scenario on the planning CT with no significant differences to OAR dose between the robust and non-robust planning techniques. All plans (robust and non-robust) achieved the mandatory target coverage requirements. Estimates of delivered dose demonstrated a significant improvement in breast target coverage for the robust plans compared to non-robust plans. For the breast CTV, 92% of the robust plans achieved the optimal D98% > 95% clinical goal as compared to 71% of the non-robust plans (p < 0.01). 94% of robust plans achieved acceptable superficial breast coverage, as compared to 55% for the non-robust technique. Conclusions: Organ motion-based robust optimisation VMAT is able to produce clinically acceptable organ-at-risk sparing plans for locoregional breast radiotherapy (including the IMC) that are robust to inter-fractional changes, therefore reducing the likelihood of reactive adaptive re-planning. Keywords: Robust optimisation, VMAT, Breast cancer, Organ-motion, IMChttp://www.sciencedirect.com/science/article/pii/S2405630819300187
collection DOAJ
language English
format Article
sources DOAJ
author Alex Dunlop
Ruth Colgan
Anna Kirby
Alison Ranger
Irena Blasiak-Wal
spellingShingle Alex Dunlop
Ruth Colgan
Anna Kirby
Alison Ranger
Irena Blasiak-Wal
Evaluation of organ motion-based robust optimisation for VMAT planning for breast and internal mammary chain radiotherapy
Clinical and Translational Radiation Oncology
author_facet Alex Dunlop
Ruth Colgan
Anna Kirby
Alison Ranger
Irena Blasiak-Wal
author_sort Alex Dunlop
title Evaluation of organ motion-based robust optimisation for VMAT planning for breast and internal mammary chain radiotherapy
title_short Evaluation of organ motion-based robust optimisation for VMAT planning for breast and internal mammary chain radiotherapy
title_full Evaluation of organ motion-based robust optimisation for VMAT planning for breast and internal mammary chain radiotherapy
title_fullStr Evaluation of organ motion-based robust optimisation for VMAT planning for breast and internal mammary chain radiotherapy
title_full_unstemmed Evaluation of organ motion-based robust optimisation for VMAT planning for breast and internal mammary chain radiotherapy
title_sort evaluation of organ motion-based robust optimisation for vmat planning for breast and internal mammary chain radiotherapy
publisher Elsevier
series Clinical and Translational Radiation Oncology
issn 2405-6308
publishDate 2019-05-01
description Aims: In patients undergoing locoregional radiotherapy (RT) for breast cancer including the internal mammary chain (IMC), VMAT has been shown to be superior to tangential-field radiotherapy in terms of target coverage and minimising dose to heart and lungs. In this study we describe and validate organ motion-based robust optimisation for generating breast and locoregional lymph node VMAT plans that are robust to inter-fractional changes. Materials and methods: In this retrospective study of five patients with left-sided breast cancer requiring locoregional breast radiotherapy including the IMC, non-robust plans were generated in the nominal scenario (planning-CT) and corresponding robust plans were created by optimising over a range of simulated CTs representing worst-case scenario shape changes to the breast. Both plans were re-calculated on CBCT images (n = 67) acquired prior to RT to generate estimates of delivered fractional dose. Plan robustness to inter-fractional changes was assessed in terms of the estimated target coverage and OAR dose. Results: Organ motion-based robust optimisation was able to generate clinically acceptable treatment plans in the nominal scenario on the planning CT with no significant differences to OAR dose between the robust and non-robust planning techniques. All plans (robust and non-robust) achieved the mandatory target coverage requirements. Estimates of delivered dose demonstrated a significant improvement in breast target coverage for the robust plans compared to non-robust plans. For the breast CTV, 92% of the robust plans achieved the optimal D98% > 95% clinical goal as compared to 71% of the non-robust plans (p < 0.01). 94% of robust plans achieved acceptable superficial breast coverage, as compared to 55% for the non-robust technique. Conclusions: Organ motion-based robust optimisation VMAT is able to produce clinically acceptable organ-at-risk sparing plans for locoregional breast radiotherapy (including the IMC) that are robust to inter-fractional changes, therefore reducing the likelihood of reactive adaptive re-planning. Keywords: Robust optimisation, VMAT, Breast cancer, Organ-motion, IMC
url http://www.sciencedirect.com/science/article/pii/S2405630819300187
work_keys_str_mv AT alexdunlop evaluationoforganmotionbasedrobustoptimisationforvmatplanningforbreastandinternalmammarychainradiotherapy
AT ruthcolgan evaluationoforganmotionbasedrobustoptimisationforvmatplanningforbreastandinternalmammarychainradiotherapy
AT annakirby evaluationoforganmotionbasedrobustoptimisationforvmatplanningforbreastandinternalmammarychainradiotherapy
AT alisonranger evaluationoforganmotionbasedrobustoptimisationforvmatplanningforbreastandinternalmammarychainradiotherapy
AT irenablasiakwal evaluationoforganmotionbasedrobustoptimisationforvmatplanningforbreastandinternalmammarychainradiotherapy
_version_ 1721403215740665856